




RealRate

PHARMACEUTICAL 2022

Spero Therapeutics Inc.
Rank 312 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of Spero Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spero Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 33% points. The greatest weakness of Spero Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is -211%, being 66% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	157,872
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,670
Liabilities, Non-Current	5,973
Other Assets	12,174
Other Compr. Net Income	5.0
Other Expenses	0
Other Liabilities	58,140
Other Net Income	-1,785
Property and Equipment	1,026
Research and Development	64,526
Revenues	18,256
Selling, General and Administrative Expense	41,701

Output Variable	Value in 1000 USD
Assets	171,072
Liabilities	82,783
Expenses	106,227
Stockholders Equity	88,289
Net Income	-89,756
Comprehensive Net Income	-89,754
Economic Capital Ratio	-211%